AxoGen, Inc. (AXGN)
AXGN Stock Price Chart
Explore AxoGen, Inc. interactive price chart. Choose custom timeframes to analyze AXGN price movements and trends.
AXGN Company Profile
Discover essential business fundamentals and corporate details for AxoGen, Inc. (AXGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
17 Dec 1986
Employees
622.00
Website
https://www.axogeninc.comCEO
Michael D. Dale
Description
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
AXGN Financial Timeline
Browse a chronological timeline of AxoGen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is $0.09, while revenue estimate is $67.10m.
Earnings released on 28 Apr 2026
EPS came in at $0.07 falling short of the estimated $0.12 by -41.67%, while revenue for the quarter reached $61.46m , beating expectations by +6.24%.
Earnings released on 24 Feb 2026
EPS came in at $0.07 falling short of the estimated $0.09 by -21.16%, while revenue for the quarter reached $59.90m , beating expectations by +1.48%.
Earnings released on 29 Oct 2025
EPS came in at $0.12 surpassing the estimated $0.09 by +33.33%, while revenue for the quarter reached $60.08m , beating expectations by +0.30%.
Earnings released on 5 Aug 2025
EPS came in at $0.12 surpassing the estimated $0.06 by +100.00%, while revenue for the quarter reached $56.66m , missing expectations by -0.40%.
Earnings released on 8 May 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $48.56m , missing expectations by -8.97%.
Earnings released on 25 Feb 2025
EPS came in at $0.08 surpassing the estimated $0.04 by +100.00%, while revenue for the quarter reached $49.41m , beating expectations by +2.33%.
Earnings released on 7 Nov 2024
EPS came in at $0.07 surpassing the estimated $0.01 by +1.07k%, while revenue for the quarter reached $48.64m , beating expectations by +2.53%.
Earnings released on 8 Aug 2024
EPS came in at $0.05 surpassing the estimated -$0.05 by +200.00%, while revenue for the quarter reached $47.91m , beating expectations by +10.42%.
Earnings released on 2 May 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $41.38m , missing expectations by -4.64%.
Earnings released on 5 Mar 2024
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $42.92m , beating expectations by +3.05%.
Earnings released on 7 Nov 2023
EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $41.27m , beating expectations by +1.45%.
Earnings released on 7 Aug 2023
EPS came in at -$0.03 surpassing the estimated -$0.15 by +80.00%, while revenue for the quarter reached $38.16m , missing expectations by -2.37%.
Earnings released on 9 May 2023
EPS came in at -$0.10 surpassing the estimated -$0.15 by +33.33%, while revenue for the quarter reached $36.66m , beating expectations by +3.66%.
Earnings released on 14 Mar 2023
EPS came in at -$0.03 surpassing the estimated -$0.10 by +70.00%, while revenue for the quarter reached $36.16m , missing expectations by -0.10%.
Earnings released on 8 Nov 2022
EPS came in at -$0.01 surpassing the estimated -$0.15 by +93.33%, while revenue for the quarter reached $36.96m , beating expectations by +2.09%.
Earnings released on 3 Aug 2022
EPS came in at -$0.06 surpassing the estimated -$0.15 by +60.00%, while revenue for the quarter reached $34.45m , beating expectations by +1.87%.
Earnings released on 4 May 2022
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $31.01m , beating expectations by +2.22%.
Earnings released on 22 Feb 2022
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $31.54m , missing expectations by -0.80%.
Earnings released on 3 Nov 2021
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $31.20m , missing expectations by -9.95%.
Earnings released on 4 Aug 2021
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $33.58m , meeting expectations.
AXGN Stock Performance
Access detailed AXGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
